Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 4, 2014

The Value of Delaying Alzheimer’s Disease Onset

  • Julie Zissimopoulos EMAIL logo , Eileen Crimmins and Patricia St.Clair


Alzheimer’s disease (AD) extracts a heavy societal toll. The value of medical advances that delay onset of AD could be significant. Using data from nationally representative samples from the Health and Retirement Study (1998–2008) and Aging Demographics and Memory Study (2001–2009), we estimate the prevalence and incidence of AD and the formal and informal health care costs associated with it. We use microsimulation to project future prevalence and costs of AD under different treatment scenarios. We find from 2010 to 2050, the number of individuals ages 70+ with AD increases 153%, from 3.6 to 9.1 million, and annual costs increase from $307 billion ($181B formal, $126B informal costs) to $1.5 trillion. 2010 annual per person costs were $71,303 and double by 2050. Medicare and Medicaid are paying 75% of formal costs. Medical advances that delay onset of AD for 5 years result in 41% lower prevalence and 40% lower cost of AD in 2050. For one cohort of older individuals, who would go on to acquire AD, a 5-year delay leads to 2.7 additional life years (about 5 AD-free), slightly higher formal care costs due to longer life but lower informal care costs for a total value of $511,208 per person. We find Medical advances delaying onset of AD generate significant economic and longevity benefits. The findings inform clinicians, policymakers, businesses and the public about the value of prevention, diagnosis, and treatment of AD.

Corresponding author: Julie Zissimopoulos, PhD, Assistant Professor, Sol Price School of Public Policy and Associate Director, Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA 90089-3331, USA, Phone: +213-821-7947, Fax: +213-740-3460, e-mail: .


All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. None of the authors have any relevant conflicts of interests. The authors’ research in this area was sponsored by the National Institute on Aging (5P30AG024968). The funding agency was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript.


Bloom, B. S., N. de Pouvourville and W. L. Straus (2003) “Cost of Illness of Alzheimer’s Disease: How Useful are Current Estimates?” Gerontologist, 43(2):158–164.10.1093/geront/43.2.158Search in Google Scholar

Brookmeyer, R., D. A. Evans, L. Herbert, K. M. Langa, S. G. Heerings, B. L. Plassman and W. A. Kukull (2011) “National Estimates of the Prevalence of Alzheimer’s Disease in the United States,” Alzheimers Dement, 7(1):61–73.10.1016/j.jalz.2010.11.007Search in Google Scholar

Butler, Robert and Jacob Brody, Delaying the Onset of Late-Life Dysfunction, Spring Publishing Company (editors R. Butler and J. Brody), New York, 1995.Search in Google Scholar

Caspi, A., K. Sugden, T. E. Moffitt, A. Taylor, I. W. Craig, H. Harrington, J. McClay, J. Mill, J. Martin, A. Braithwaite, and R. Poulton (2003) “Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT gene,” Science, 301(5631):386–389.10.1126/science.1083968Search in Google Scholar

Fisher G., H. Hassan, W. Rodgers, and D. Weir. Health and Retirement Study Imputation of Cognitive Functioning Measures 1992–2010. 2013; available on-line at in Google Scholar

Goldman D. P., J. Zissimopoulos and Y. Lu (2011) “Medical Expenditure Measures in the Health and Retirement Study,” Forum for Health Economics and Policy, 14(3):4.10.2202/1558-9544.1267Search in Google Scholar

Goldman, D. P., B. Shang, J. Bhattacharya, A. M. Garber, M. Hurd, G. Joyce, et al. (2005) “Consequences of Health Trends and Medical Innovation for the Future Elderly,” Health Affairs (Millwood), 24:w5-r5-17. DOI:10.1377/hlthaff.w5r5.Search in Google Scholar

Hebert, L., J. Weuve, P. Scherr and D. Evans (2013) “Alzheimer’s Disease in the United States (2010-2050) Estimated Using the 2010 Census,” Neurology, 10.1212/WNL.0b013e31828726f52013.Search in Google Scholar

Heeringa S. G., G. G. Fisher, M. Hurd, K. M. Langa, M. B. Ofstedal, B. L. Plassman, et al. (2010) Aging, Demographics, and Memory Study (ADAMS): Sample Design, Weighting and Analysis for ADAMS. Ann Arbor: University of Michigan Survey Research Center, Institute for Social Research.10.7826/ISR-UM.06.585031.001.05.0019.2009Search in Google Scholar

Hurd M. D., P. Martorell, A. Delavande, K. Mullen and K. Langa (2013) “Monetary Costs of Dementia in the United States,” New England Journal of Medicine, 368:1326–1334.10.1056/NEJMsa1204629Search in Google Scholar

Langa, K. M., B. L. Plassman, R. B. Wallace, A. R. Herzog, S. Heeringa, et al. (2005) “The Aging Demographics and Memory Study: Study Design and Methods,” Neuroepidemiology, 25(4):181–191.10.1159/000087448Search in Google Scholar

Lin, P. J. and P. J. Neumann (2013) “The Economics of Mild Cognitive Impairment,” Alzheimers and Dementia, 9(1):58–62.10.1016/j.jalz.2012.05.2117Search in Google Scholar

Ofstedal, M. B., G. Fisher, A. R. Herzog. Documentation of Cognitive Functioning Measures in the Health and Retirement Study. 2005; available on-line at in Google Scholar

Ostbye, T., D. H. Taylor, E. Clipp, L. Van Scoyoc and B. Plassman (2008) “Identification of Dementia: Agreement Among National Survey Data, Medicare Claims, and Death Certificates,” Health Services Research, 43(1 Pt 1):313–326.10.1111/j.1475-6773.2007.00748.xSearch in Google Scholar

Plassman B. L., K. M. Langa, G. G. Fisher, S. G. Heeringa, D. R. Weir, M. B. Ofstedal, et al. (2007) “Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study,” Neuroepidemiology, 29:125–132.10.1159/000109998Search in Google Scholar

Plassman, B. L., K. M. Langa, G. G. Fisher, S. G. Heeringa, D. R. Weir, M. B. Ofstedal, et al. (2008) “Prevalence of Cognitive Impairment Without Dementia in the United States,” Annals of Internal Medicine, 148(6):427–434.10.7326/0003-4819-148-6-200803180-00005Search in Google Scholar

Schulz, R. and L. M. Martire (2004) “Family Caregiving of Persons with Dementia: Prevalence, Health Effects, and Support Strategies,” American Journal of Geriatric Psychiatry, 12(3):240–249.10.1097/00019442-200405000-00002Search in Google Scholar

Taylor, D. H., Jr., T. Ostbye, K. Langa, D. Weir and B. Plassman (2009) “The Accuracy of Medicare Claims as an Epidemiological Tool: The Case of Dementia Revisited,” Journal of Alzheimers Disease, 17(4):807–815.10.3233/JAD-2009-1099Search in Google Scholar

Wilson, R. S., D. R. Weir, S. E. Leurgans, D. A. Evans, L. E. Herbert, K. M. Langa, et al. (2011) “Sources of Variability in Estimates of the Prevalence of Alzheimer’s Disease in the United States,” Alzheimers and Dementia, 7(1):74–79.10.1016/j.jalz.2010.11.006Search in Google Scholar

Xu, J., M. Chatterjee, T. D. Baguley, J. Brouillette, P. Kurup, D. Ghosh, J. Kanyo, Y. Zhang, K. Seyb, C. Ononenyi, E. Foscue, G. M. Anderson, J. Gresack, G. D. Cuny, M. A. Glicksman, P. Greengard, T. T. Lam, L. Tautz, A. C. Nairn, J. A. Ellman and P. J. Lombroso (2014) “Inhibitor of the Tyrosine Phosphatase STEP Reverses Cognitive Deficits in a Mouse Model of Alzheimer’s Disease,” PLoS Biology, 12(8):e1001923 DOI: 10.1371/journal.pbio.1001923.10.1371/journal.pbio.1001923Search in Google Scholar

Supplemental Material

The online version of this article (DOI: 10.1515/fhep-2014-0013) offers supplementary material, available to authorized users.

Published Online: 2014-11-4
Published in Print: 2015-1-1

©2015 by De Gruyter

Downloaded on 8.12.2023 from
Scroll to top button